AR052643A1 - Memantina para el tratamiento de trastornos de conducta en la infancia - Google Patents

Memantina para el tratamiento de trastornos de conducta en la infancia

Info

Publication number
AR052643A1
AR052643A1 ARP050103986A ARP050103986A AR052643A1 AR 052643 A1 AR052643 A1 AR 052643A1 AR P050103986 A ARP050103986 A AR P050103986A AR P050103986 A ARP050103986 A AR P050103986A AR 052643 A1 AR052643 A1 AR 052643A1
Authority
AR
Argentina
Prior art keywords
memantine
child
treatment
conduct disorders
disorders
Prior art date
Application number
ARP050103986A
Other languages
English (en)
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35445934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR052643(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of AR052643A1 publication Critical patent/AR052643A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método para el tratamiento de individuos con diagnostico de trastorno de conducta infantil, tal como los trastornos del espectro autista o la forma combinada del trastorno de déficit de atencion de hiperactividad (ADHD) mediante la administracion de una cantidad eficaz de memantina.
ARP050103986A 2004-09-23 2005-09-26 Memantina para el tratamiento de trastornos de conducta en la infancia AR052643A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61260004P 2004-09-23 2004-09-23

Publications (1)

Publication Number Publication Date
AR052643A1 true AR052643A1 (es) 2007-03-28

Family

ID=35445934

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103986A AR052643A1 (es) 2004-09-23 2005-09-26 Memantina para el tratamiento de trastornos de conducta en la infancia

Country Status (16)

Country Link
US (2) US20060079582A1 (es)
EP (1) EP1799224A1 (es)
JP (1) JP2008514620A (es)
KR (1) KR20070046185A (es)
CN (1) CN101374525A (es)
AR (1) AR052643A1 (es)
AU (1) AU2005286672B2 (es)
BR (1) BRPI0515560A (es)
CA (1) CA2578953A1 (es)
EA (1) EA012036B1 (es)
IL (1) IL182105A0 (es)
MX (1) MX2007003267A (es)
NO (1) NO20072035L (es)
TW (1) TW200626160A (es)
WO (1) WO2006034465A1 (es)
ZA (1) ZA200702130B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7456224B2 (en) 2004-04-05 2008-11-25 Forest Laboratories Holdings, Ltd. Method for treating autism
EP2040676A2 (en) * 2006-07-06 2009-04-01 Forest Laboratories, Inc. Orally dissolving formulations of memantine
RU2326660C1 (ru) * 2007-03-14 2008-06-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты)
US20100292341A1 (en) * 2007-06-29 2010-11-18 Orchid Chemicals & Pharmaceuticals Limited Quick dissolve compositions of memantine hydrochloride
WO2009151498A2 (en) * 2008-03-28 2009-12-17 Forest Laboratories Holdings Limited Memantine formulations
EP2138173A1 (en) 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
HUE032888T2 (hu) 2008-12-08 2017-11-28 Biocodex Vegyületek és eljárások autizmus spektrum zavarok kezelésére
IT1396556B1 (it) * 2009-02-11 2012-12-14 Serra Uso di memantina per il trattamento di disturbi dell umore
EP3034079B1 (en) 2010-11-15 2018-01-10 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
WO2014015047A1 (en) 2012-07-17 2014-01-23 The General Hospital Corporation Compositions and methods to treat neurodegenerative diseases
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
KR101424514B1 (ko) * 2013-01-02 2014-07-31 건국대학교 산학협력단 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도
EP3485882A1 (en) 2013-01-25 2019-05-22 Case Western Reserve University Compositions for the treatment of pervasive development disorders
WO2014153180A1 (en) * 2013-03-14 2014-09-25 Michela Gallagher Methods and compositions for improving cognitive function
CA2934553C (en) 2013-12-20 2023-10-31 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
ES2909456T3 (es) * 2015-05-22 2022-05-06 Univ Arizona State Métodos para tratar el trastorno del espectro autista y síntomas asociados
MX2017015752A (es) 2015-06-19 2018-04-13 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo.
KR20190040237A (ko) 2016-08-24 2019-04-17 조게닉스 인터내셔널 리미티드 5-ht2b 작용물질의 형성을 억제하기 위한 제제 및 그것의 사용 방법
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
KR20200043401A (ko) * 2017-08-01 2020-04-27 스튜어트 에이. 립튼 신경 질환을 치료하기 위한 방법 및 조성물
US20190091179A1 (en) * 2017-09-26 2019-03-28 Zogenix International Limited Congnitive function with fenfluramine
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
MX2020013927A (es) 2018-06-19 2021-03-02 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH603545A5 (es) * 1972-04-20 1978-08-31 Merz & Co
HU169986B (es) * 1972-12-07 1977-03-28
DE2856393C2 (de) * 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US6024983A (en) * 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US4849222A (en) * 1987-03-24 1989-07-18 The Procter & Gamble Company Mixtures for treating hypercholesterolemia
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
ATE94384T1 (de) * 1989-04-14 1993-10-15 Merz & Co Gmbh & Co Verwendung von adamantan-derivaten zur praevention und behandlung der cerebralen ischaemie.
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US6057373A (en) * 1997-05-22 2000-05-02 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists
US6326226B1 (en) * 1997-07-15 2001-12-04 Lg. Philips Lcd Co., Ltd. Method of crystallizing an amorphous film
WO1999036064A2 (en) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders
US6362226B2 (en) * 1999-12-08 2002-03-26 Vanderbilt University Modulation of in vivo glutamine and glycine levels in the treatment of autism
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
EP1471909A4 (en) * 2002-01-16 2007-07-25 Endo Pharmaceuticals Inc PHARMACEUTICAL COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
TW200410672A (en) * 2002-07-19 2004-07-01 Merz Pharma Gmbh & Co Kgaa NMDA receptor antagonists and their use in inhibiting abnormal hyperphosphorylation of microtubule associated protein tau
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease

Also Published As

Publication number Publication date
EP1799224A1 (en) 2007-06-27
WO2006034465A8 (en) 2006-06-08
AU2005286672A1 (en) 2006-03-30
US20060079582A1 (en) 2006-04-13
CN101374525A (zh) 2009-02-25
IL182105A0 (en) 2007-07-24
JP2008514620A (ja) 2008-05-08
MX2007003267A (es) 2007-05-23
EA012036B1 (ru) 2009-06-30
BRPI0515560A (pt) 2008-07-29
KR20070046185A (ko) 2007-05-02
AU2005286672B2 (en) 2009-03-12
NO20072035L (no) 2007-06-13
ZA200702130B (en) 2008-09-25
EA200700708A1 (ru) 2007-08-31
WO2006034465A1 (en) 2006-03-30
US20100081723A1 (en) 2010-04-01
CA2578953A1 (en) 2006-03-30
TW200626160A (en) 2006-08-01

Similar Documents

Publication Publication Date Title
AR052643A1 (es) Memantina para el tratamiento de trastornos de conducta en la infancia
AR050623A1 (es) Metodo para el tratamiento del trastorno de hiperactividad de deficit de atencion
UY31497A1 (es) Nuevos compuestos para el tratamiento de trastornos del snc
BR112016029498A2 (pt) canabidiol, método para tratamento de epilepsia, e, composição.
ECSP10010526A (es) Compuesto heterociclico
BRPI0606542A2 (pt) métodos para aumentar o tempo de progressão de uma doença (ttp) ou a sobrevivência, uso de um inibidor da dimerização de her e uso de pertuzumab
ECSP12012160A (es) Compuesto heterociclico
CR20140223A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
UY33199A (es) 5-alquinil-pirimidinas.
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
BR112022003505A2 (pt) Composições e métodos para tratamento de distúrbios associados a dna repetitivo
UY33017A (es) Tratamiento para trastornos gastrointestinales
ECSP10010704A (es) Sales y polimorfos de un compuesto de tetraticlina
ECSP10010730A (es) Hidrogenación de alcanos multi-bromados
UY35518A (es) Composicion de hidrocarburos renovable
ECSP11010786A (es) 5-alquinil-pirimidinas
CL2012001031A1 (es) Compuestos derivados de 2-oxo-1-pirrolidinil-imidazotiadiazol; composición farmacéutica que los comprende; útiles para el tratamiento de la epilepsia, transtornos neurológicos, entre otros.
CL2014003429A1 (es) Compuestos especificos derivados de indanosulfamida; composicion farmaceutica que los comprende, utiles en el tratamiento e la epilepsia.
ECSP11010816A (es) Nuevos Compuestos
CL2016001578A1 (es) Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c.
BR112012014621B8 (pt) Processo para a preparação de compostos de quelato
AR100734A1 (es) Método para tratar leucemia linfocítica crónica (cll)
UY31700A (es) Tiazolil-dihidro-indazoles
CL2009001018A1 (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia, teniendo los pacientes un incremento del nivel de creatinina debido a la utilizacion de dronedarona.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal